Document Detail

Active disease requiring TNF-alpha-antagonist therapy can be well discriminated with different ASDAS sets: a prospective, follow-up of disease activity assessment in ankylosing spondylitis.
MedLine Citation:
PMID:  20863448     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: To evaluate the validity of different ASDAS sets to assess disease activity in ankylosing spondylitis (AS) in comparison to standard activity assessment tools in routine clinical setting and to determine the best cut-off values for deciding active disease requiring TNF-α antagonist therapy.
METHODS: Two hundred consecutive AS patients (M/F:104/96) were enrolled. Mean (SD) age was 40.3 (11.7) and disease duration was 11 (8.5) years. Disease activity was assessed by four different ASDAS sets, BASDAI, patient and physicians' global assessments, ESR and CRP. The correlation between different parameters and ASDAS scores of patients requiring TNF-α antagonist therapy were determined.
RESULTS: At the time of the assessment 18.5% of the patients were only having NSAIDs, 43% were receiving sulphasalazine and/or methotrexate and 38.5% were under TNF-α antagonists. After the evaluation, 36 (18%) patients were decided to require TNF-α antagonist therapy, 33 (16.5%) patients were started sulphasalazine or methotrexate or their dose increased and 131 (65.5%) patients were decided to be stable without any requirement for a change in therapy. The patients requiring new-TNFα antagonist therapy had significantly higher ASDAS values. The ROC curve analysis revealed best-cut off values for ASDAS sets (ASDAS A: 3.28, ASDAS B: 3.07, ASDAS C: 2.38 and ASDAS D: 3.1) When standardised mean differences were compared, ASDAS B was the best set within the others, but not significantly different from other ASDAS sets and standard assessment tools except acute-phase reactants.
CONCLUSIONS: ASDAS sets perform well to discriminate TNF-α antagonist requirement in advanced AS patients. However BASDAI and patient's or physician's global assessments also had acceptable performances in our clinical setting.
S Z Aydin; M Can; P Atagunduz; H Direskeneli
Related Documents :
20472718 - Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated m...
19891528 - Thrombopoietic cytokines and platelet count in multiple myeloma.
9345418 - Campath-ih in multiple sclerosis.
17050638 - Factors involved in vascular calcification and atherosclerosis in maintenance haemodial...
17207238 - Predictors of response and relapse in a cohort of adults with thrombotic thrombocytopen...
836118 - The pathophysiology and clinical characteristics of severe hypophosphatemia.
Publication Detail:
Type:  Journal Article; Validation Studies     Date:  2010-10-22
Journal Detail:
Title:  Clinical and experimental rheumatology     Volume:  28     ISSN:  0392-856X     ISO Abbreviation:  Clin. Exp. Rheumatol.     Publication Date:    2010 Sep-Oct
Date Detail:
Created Date:  2010-10-29     Completed Date:  2010-12-14     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8308521     Medline TA:  Clin Exp Rheumatol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  752-5     Citation Subset:  IM    
Academic Unit of Musculoskeletal disease, University of Leeds, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / therapeutic use*
Antirheumatic Agents / therapeutic use*
Disability Evaluation
Follow-Up Studies
Health Status
Prospective Studies
Quality of Life
ROC Curve
Severity of Illness Index
Spondylitis, Ankylosing / diagnosis*,  physiopathology
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antirheumatic Agents; 0/Tumor Necrosis Factor-alpha

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Persistence on therapy is a major determinant of patient-, physician- and laboratory- reported outco...
Next Document:  A reappraisal of intra-articular corticosteroid therapy in juvenile idiopathic arthritis.